WooGene B&G Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021
March 22, 2022 at 10:24 am IST
Share
WooGene B&G Co., Ltd reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was KRW 2,258.33 million compared to KRW 2,063.81 million a year ago. Basic loss per share from continuing operations was KRW 78 compared to KRW 110 a year ago.
Basic loss per share was KRW 78 compared to KRW 78 a year ago. Diluted loss per share was KRW 78 compared to KRW 78 a year ago.
WooGene B&G Co., Ltd. is a Korea-based company mainly engaged in the manufacture of veterinary drugs. The Companyâs products include anti-infective, bulk materials, probiotics, enzymes, antiparasitics, hormone preparations, vaccines, aquacultures, anesthetics, teat dips, disinfectants, pet cure drugs, calcium injections, antiphlogistic injections, enhance metabolism injections, diarrhea remedy injections, sedative injections for swine, toxin binders, pigmentation drugs and others. The Company also provides anti-inflammatory enzymes under the brand name SKD, which are used for human beings. The Company distributes its products within domestic market and to overseas markets, including Iran, Vietnam, Philippines, Brazil and others.
WOOGENE B&G CO., LTD 
